Not so puzzling: Actavis, Forest pieces fit strategic gaps
This article was originally published in Scrip
Executive Summary
The $25bn merger of brand-name drug marketer Forest Laboratories into generics maker Actavis isn't so puzzling, considering Actavis's increased focus on specialty medicines and the pent-up demand for significant returns for Forest shareholders.
You may also be interested in...
Pharma Dealmaker Saunders Includes Wellness Space In Acquisition Group’s Investment Targets
Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.
Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.